Brufsky AM - Search Results

1

Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.

Farrugia DJ, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R. Farrugia DJ, et al. Among authors: brufsky am. Mod Pathol. 2017 Aug;30(8):1078-1085. doi: 10.1038/modpathol.2017.41. Epub 2017 May 26. Mod Pathol. 2017. PMID: 28548119 Free article.

2

Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.

Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE. Brufsky A, et al. Clin Breast Cancer. 2005 Aug;6(3):247-52. doi: 10.3816/CBC.2005.n.027. Clin Breast Cancer. 2005. PMID: 16137436

3

Single-fraction radiosurgery for the treatment of spinal breast metastases.

Gerszten PC, Burton SA, Welch WC, Brufsky AM, Lembersky BC, Ozhasoglu C, Vogel WJ. Gerszten PC, et al. Among authors: brufsky am. Cancer. 2005 Nov 15;104(10):2244-54. doi: 10.1002/cncr.21467. Cancer. 2005. PMID: 16216003 Free article.

4

Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.

Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ. Esposito NN, et al. Arch Pathol Lab Med. 2006 Oct;130(10):1516-21. doi: 10.5858/2006-130-1516-PTACAI. Arch Pathol Lab Med. 2006. PMID: 17090194 Free article.

5

Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases.

Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ. Chivukula M, et al. Mod Pathol. 2008 Apr;21(4):363-8. doi: 10.1038/modpathol.3801021. Epub 2008 Feb 1. Mod Pathol. 2008. PMID: 18246053 Free article.

6

Histopathologic variables predict Oncotype DX recurrence score.

Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Flanagan MB, et al. Among authors: brufsky am. Mod Pathol. 2008 Oct;21(10):1255-61. doi: 10.1038/modpathol.2008.54. Mod Pathol. 2008. PMID: 18360352 Free article.

7

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.

Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, Sereika SM, Vogel VG. Greenspan SL, et al. J Clin Oncol. 2008 Jun 1;26(16):2644-52. doi: 10.1200/JCO.2007.15.2967. Epub 2008 Apr 21. J Clin Oncol. 2008. PMID: 18427147 Free PMC article. Clinical Trial.

8

Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.

Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Chivukula M, et al. Am J Surg Pathol. 2008 Nov;32(11):1721-6. doi: 10.1097/PAS.0b013e31817dc3a6. Am J Surg Pathol. 2008. PMID: 18769331

9

Bevacizumab in breast cancer: the best is yet to come?

Puhalla S, Brufsky A. Puhalla S, et al. Oncology (Williston Park). 2009 Apr 15;23(4):332, 335. Oncology (Williston Park). 2009. PMID: 19476262 Free article. No abstract available.

10

Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.

Brufsky A. Brufsky A. Am J Clin Oncol. 2010 Apr;33(2):186-95. doi: 10.1097/COC.0b013e318191bfb0. Am J Clin Oncol. 2010. PMID: 19675448 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

362 results

Search Page

Filters